Currently, there are 2 analysts that have provided ratings for Loxo Oncology, Inc. (NASDAQ:LOXO). 3 have rated the stock a “Strong Buy”, 0 rate it a “Buy”, 0 are putting a Hold rating on the stock, and 0 are recommending “Sell”. Every recommendation ...
Zacks has a rating methodology wherein it gives a 1-5 rating to the stock. As per this methodology, any score of 1 or 2 means a Buy call, a score of 4 or 5 gives sell indication, and a score of 3 implies a recommendation to hold stock. The Buy calls ...
STAMFORD, Conn., April 27, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...
STAMFORD, Conn., April 27, 2016 (GLOBE NEWSWIRE) — Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...
STAMFORD, Conn., April 27, 2016 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial ...
The stock of Loxo Oncology Incorporated (NASDAQ:LOXO) registered an increase of 9.82% in short interest. LOXO's total short interest was 1.30M shares in April as published by FINRA. Its up 9.82% from 1.18M shares, reported previously. With 215,500 ...